FDA Approves First Drug for Graft vs. Host Disease Prevention

Published on December 15, 2021

The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Bristol Myers Squibb Co.’s drug Orencia to prevent a potentially fatal complication that could occur after a stem cell transplant. The approval makes Orencia the first drug for the prevention of…

Read Full Article (External Site)